Industry News

Biotechnology Industry News

AbbVie released positive phase 3…

September 3rd, 2026|FierceBiotech|

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/refractory multiple myeloma.

Ultragenyx had been flying high…

September 3rd, 2026|FierceBiotech|

Ultragenyx had been flying high after its recent FDA approval for Genglycos—but the company has been brought back down to earth with a damaging phase 3 flop.

H1 is transforming clinical…

September 2nd, 2026|FierceBiotech|

H1 is transforming clinical development with connected intelligence that improves study design, accelerates execution, and reduces cost and patient burden

Teva Pharmaceutical’s dreams of a…

September 2nd, 2026|FierceBiotech|

Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s anti-interleukin-15 antibody scored a midstage win in celiac disease.

The SEC and the FDA have signed a…

September 2nd, 2026|FierceBiotech|

The SEC and the FDA have signed a three-year agreement to step up cooperation and information-sharing capabilities aiming to improve each organization’s regulatory and enforcement missions.

TCR-T specialist TScan…

September 2nd, 2026|FierceBiotech|

TCR-T specialist TScan Therapeutics will reduce its workforce by 75% following the pause of its hematological and autoimmune programs.

Novartis has struck a deal worth…

September 2nd, 2026|FierceBiotech|

Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and GSK on the list of drugmakers to pay to access the technology this year.

The overwhelming demand for GLP-1…

September 1st, 2026|FierceBiotech|

The overwhelming demand for GLP-1 weight loss drugs has reshaped the drug market, empowering consumers to take charge of their own health and removing barriers between their wallets and their medicine cabinets.

The announcement from Merck &…

September 1st, 2026|FierceBiotech|

The announcement from Merck & Co. and Moderna last month that their mRNA cancer vaccine had successfully lengthened patient survival in a phase 3 study affirmed the two companies' years of hard work and reignited

Roche is paying oncology-focused…

September 1st, 2026|FierceBiotech|

Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases.

About a year after halving its…

September 1st, 2026|FierceBiotech|

About a year after halving its staff in a clinical push, Arsenal Biosciences is now making a hard pivot that involves laying off most of its employees and seeking out new homes for its assets.

A phase 2b lupus trial of…

September 1st, 2026|FierceBiotech|

A phase 2b lupus trial of Alumis’ envudeucitinib has missed its primary and secondary endpoints. But the biotech is still moving the TYK2 inhibitor into phase 3 in the autoimmune disease, pointing to evidence of

GSK has linked its mRNA seasonal…

September 1st, 2026|FierceBiotech|

GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, emboldening the company to start a pivotal study this month.

Three deaths have forced Novartis…

August 31st, 2026|FierceBiotech|

Three deaths have forced Novartis to pause development of its CD19 CAR-T candidate in autoimmune diseases, just as Bristol Myers Squibb has halted a similar program due to immune-related adverse events, Fierce has learned.

As AstraZeneca appears to close…

August 31st, 2026|FierceBiotech|

As AstraZeneca appears to close the book on a combo approach following the phase 3 failure of its Ionis-partnered Wainua, several analysts contend it’s too early to count out Alnylam’s silencing drugs in ATTR-CM patients

AstraZeneca’s oral relaxin…

August 31st, 2026|FierceBiotech|

AstraZeneca’s oral relaxin agonist delivered encouraging phase 2b results in chronic heart failure, improving measures of cardiac function across two patient groups.

Eli Lilly has struck a deal to…

August 31st, 2026|FierceBiotech|

Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to treat disease through the selective degradation of pathogenic autoantibodies.